ELVN:NSD-Enliven Therapeutics Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 21.47

Change

-0.91 (-4.07)%

Market Cap

N/A

Volume

0.15M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-7.94 (-0.69%)

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

-7.10 (-1.48%)

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

-1.31 (-0.48%)

USD 35.24B
ARGX argenx NV ADR

+6.84 (+1.31%)

USD 32.19B
MRNA Moderna Inc

-2.13 (-2.96%)

USD 26.25B
SMMT Summit Therapeutics PLC

-1.66 (-6.33%)

USD 23.47B
BGNE BeiGene Ltd

-0.23 (-0.12%)

USD 21.94B
RPRX Royalty Pharma Plc

-0.03 (-0.11%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.59 (+0.84%)

USD 16.16B
UTHR United Therapeutics Corporatio..

-2.43 (-0.70%)

USD 15.09B

ETFs Containing ELVN

CNCR Loncar Cancer Immunothera.. 2.76 % 0.79 %

-0.25 (-1.60%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 55.13% 84% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.13% 84% B 91% A-
Trailing 12 Months  
Capital Gain 50.14% 77% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.14% 77% C+ 86% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.28% 58% F 52% F
Dividend Return 3.28% 57% F 48% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.83% 99% N/A 83% B
Risk Adjusted Return 22.13% 78% C+ 56% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector